Visit the Veristat booth #19 at the Clinical Operations in Oncology West conference taking place on April 30 and May 1 in Burlingame, CA
Employees at Veristat handle complex work that is both rewarding and meaningful. Our team members are dedicated partners to internal colleagues and external clients alike.
Our values include:
If this sounds like an environment you would thrive in, then click below to learn more about us.
Since the day Veristat was formed, our approach has focused on partnership. We aren’t here to complicate your studies, we are here to be a true extension of your team, to build enduring partnerships, to be a trust-worthy teacher and respected team member.
We are here to be TRUE Partners to You.
Our teams support innovative, life-enhancing, and life-saving therapies that range from novel vaccines for global pandemics to new approaches for treating fungal infections to the latest immunotherapies to eradicate cancer. We have the right expertise and therapeutic understanding and creative know-how to help you design, build, and run your clinical development program in any therapeutic area.
Our core therapeutic Centers of Excellence include: Cancers, Rare Diseases, CNS Disorders, Cardiovascular Disease, Infectious Diseases and more.
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) and European Medicines Agency (EMA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided in March 2019.
At Veristat our need to manage and work in virtual environments continues to increase. With six offices globally and nearly 300 employees, we are building teams with members spread out in different physical locations. Our geographically dispersed teams continue to grow with our increasing remote employee population; In fact remote workers are our largest growing population with nearly 30 % of our employees working from their home offices.